As clinical trials progress, Pendulum hopes their medical evidence can beat the status quo and encourage Americans to take preventative care into their own hands.
There is a huge boom in the newfound 'GLP-1 supplements' industry, and New Zealander CaloCurb is taking advantage, seeing 400% to 600% growth per quarter. They are now in the middle of their fourth, and largest, human trial - but will strong clinical results be enough to capture the market?
Lexicon has been discovering new genetic science since the Human Genome Project. They've retained investor interest, and have 2 solid new FDA approvals. Dr. Mike Exton, with over 2 decades of pharma experience, was drafted in this Summer and has plans to make history... in 2025 Lexicon is
